Inobrodib [2222941-37-7]
Cat# NB-64-01928-1mg
Size : 1mg
Brand : Neo Biotech
Contact local distributor :
Phone : +1 850 650 7790
Inobrodib (Synonyms: CCS1477, CBP-IN-1)
Catalog No. T10717 Copy Product Info
Purity: 99.18%
Inobrodib (CBP-IN-1) is a potent inhibitor of p300/CBP bromodomain.
Inobrodib
Copy Product InfoSynonyms CCS1477, CBP-IN-1
Inobrodib (CBP-IN-1) is a potent inhibitor of p300/CBP bromodomain.
Cas No. 2222941-37-7
Select Batch
Purity:99.18%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Inobrodib AI Summary
Inobrodib demonstrates antiviral activity against SARS-CoV-2 induced cytotoxicity in VERO-E6 cells, although it did not show a significant inhibitory effect at a concentration of 10 µM, with an IC50 value exceeding 100,000 nM. This compound also exhibited moderate cytotoxicity against VERO-E6 cells with a CC50 value of 3160 nM. Additionally, Inobrodib shows potent inhibitory activity against the human CBP bromodomain with an IC50 value of 2.05 nM and a dissociation constant (Kd) of 14.0 nM. It exhibits antiproliferative activities against various human cancer cell lines, including LNCaP C4-2B (IC50 = 1650.0 nM), LNCaP (IC50 = 60.0 nM), and 22Rv1 (IC50 = 420.0 nM) by inhibiting cell growth. The compound also affects the thermal stability of various bromodomains, as evidenced by changes in melting temperatures in thermal shift assays..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Inobrodib (CBP-IN-1) is a potent inhibitor of p300/CBP bromodomain. |
| Synonyms | CCS1477, CBP-IN-1 |
| Molecular Weight | 534.6 |
| Formula | C30H32F2N4O3 |
| Cas No. | 2222941-37-7 |
| Smiles | CO[C@H]1CC[C@@H](CC1)n1c(nc2cc(ccc12)-c1c(C)noc1C)[C@@H]1CCCC(=O)N1c1ccc(F)c(F)c1 |
| Relative Density. | 1.37 g/cm3 (Predicted) |
| Storage | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (187.06 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (9.35 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
You might also be interested by the following products:
Cat#
Description
Cond.
Price Bef. VAT